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The optimal first-line treatment for symptomatic patients with advanced stage follicular lymphoma remains unclear. Fludarabine-based
combination regimens have been extensively used in relapsed disease and merit consideration as first-line therapy. We here report
the results of a phase II study of FAD (fludarabine, adriamycin, dexamethasone) regimen in 30 patients with advanced stage follicular
lymphoma requiring treatment. The response rate was in excess of 90% with 39% achieving a complete remission. The major toxicity
was myelosuppression, but only 3% of cycles were associated with grade IV leucopenia. The high response rate has not translated
into major improvements in failure-free survival and consideration must be given to alternative treatment modalities to consolidate
the high rate of initial responses.
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Follicular lymphoma remains a disease of relapses and remissions,
and despite new modalities of therapy a plateau in the survival
curve has yet to become apparent. Treatment with the alkylating
agents chlorambucil and cyclophosphamide have been the
mainstay of therapy for many years. Nucleoside analogues such
as fludarabine offer an alternative, noncrossresistant option.
Fludarabine has been shown to be effective in low-grade non-
Hodgkin’s lymphomas although results are disappointing when it
has been used as single agent first-line therapy (Solal-Celigny et al,
1996). In an Intergroup randomised trial, fludarabine resulted in a
better response rate than CVP (cyclophosphamide, vincristine and
prednisolone), but this did not translate into improved time to
treatment failure or overall survival (OS) (Marcus et al, 2002).
McLaughlin et al reported good results using fludarabine in
combination with mitoxantrone and dexamethasone (FMD/FND)
in patients with recurrent disease. The phase I study in 21 patients
receiving up to eight courses of FMD reported a 43% complete
remission (CR) rate with these remissions lasting a median of 18
months (McLaughlin et al, 1994). These results were confirmed in
the phase II study of 51 patients with recurrent or refractory
indolent lymphoma, which reported a response rate of 98%, with
attainment of CR in 47% (McLaughlin et al, 1996). Another phase
II study evaluated FMD in 54 mainly pretreated patients, and
reported an overall response rate of 69%, with complete responses
seen in 11 (20%) patients (Crawley et al, 2000). Treatment toxicity
was not uncommon with these combination regimens. In the
McLaughlin study, there were six recorded cases of Herpes zoster
infection and six cases of proven or suspected Pneumocystis carinii
in 257 courses of treatment. As a result of these opportunistic
infections, cotrimoxazole prophylaxis was introduced towards the
end of the trial period (McLaughlin et al, 1996). In the Crawley
study, chemotherapy was delayed in five and discontinued in a
further five patients due to prolonged cytopenia. A total of 18
patients required inpatient admission for treatment of neutropenic
fever (Crawley et al, 2000).
There is relatively little information about fludarabine, anthra-
cyline/anthracenedione and steroid-containing combination che-
motherapy regimens as first-line therapy. The patients in the
McLaughlin study were all pretreated and there were only 10
chemotherapy naive patients in the Crawley study. Velasquez et al
(2003) and Zinzani et al (2000) conducted studies in previously
untreated patients with 78 and 27 patients, respectively, but they
used fludarabine and mitoxantrone only, omitting the steroids
which can have potent lympholytic activity (Cline, 1973; Green-
stein et al, 2002).
There has been controversy about the relative merits of
mitoxantrone and adriamycin in the treatment of lymphomas
(Sonneveld et al, 1995; Mainwaring et al, 2001; Osby et al, 2003),
and in this trial adriamycin was used instead of mitoxantrone in
view of the lesser myelosuppression reported by Mainwaring et al
(2001) at the doses used.
PATIENTS AND METHODS
Patients over the age of 18 years with newly presenting follicular
non-Hodgkin’s lymphoma, types B–D according to the Working
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lFormulation, with stage III–IV disease requiring therapy were
eligible for this trial.
Atotal of 35 patients were entered, with a median age of 55 years
(range 29–76). There were 21 (60%) male and 14 (40%) female
patients. All histopathology specimens were centrally reviewed,
and after such review five patients were excluded (three mantle cell
lymphomas, one large cell lymphoma, one insufficient material).
This report is based on the 30 eligible patients with a confirmed
diagnosis of follicular lymphoma. In all, 16 (46%) patients had
stage III disease and 19 (54%) had stage IV disease. All were judged
as requiring treatment (progressive disease over at least 3 months,
critical organ involvement, bone marrow failure or ‘B’ symptoms.)
A total of 19 patients (58%) had WHO performance status of 0.
Patients were excluded from this study if they were suffering
from any irreversible medical condition that was likely to be fatal
within the next 5 years or which would preclude the use of
combination chemotherapy. Patients with impaired renal function
(creatinine 4150gmoll
 1), hepatic impairment (bilirubin
435gmoll
 1) or cardiac dysfunction (previous history and
MUGA o40%) not due to involvement with follicular lymphoma
were excluded from this study. Other exclusion criteria were a
diagnosis of a previous malignancy or non-Hodgkin’s lymphoma
affecting the central nervous system.
The patient characteristics are shown in Table 1.
Trial design
This was a single arm study of the toxicity and efficacy of the
nucleoside analogue fludarabine monophosphate in combination
with adriamycin and dexamethasone (FAD). The primary end
point was regimen-related toxicity with a secondary end point of
failure-free survival (FFS).
The treatment schedule of ‘FAD’ comprised fludarabine
25mgm
 2 intravenously on days 1–3, adriamycin 50mgm
 2
intravenously on day 1, and dexamethasone 20mg orally or
intravenously from days 1–5. Co-trimoxazole, 480mg b.i.d. thrice
weekly throughout treatment and for 8 weeks following completion
of therapy, was given as prophylaxis against Pneumocystis carinii
infection. Allopurinol 300mg once daily orally was also adminis-
tered for the first week of each course of chemotherapy. Courses
were given on a 28-day cycle until CR was achieved, with two
courses given beyond remission as remission consolidation. Thus,
patients received a minimum of four and a maximum of eight
cycles of chemotherapy.
All blood products required were irradiated to a minimum of
25Gy. Any significant pleural effusions or abdominal ascites were
drained to dryness prior to commencement of fludarabine therapy.
The first course of chemotherapy was given at full dose. In the
event of haematological toxicity, dose modifications for subse-
quent courses were made as follows: treatment was deferred if the
neutrophil level was o1.5 10
9l
 1 or platelet count
o100 10
9l
 1. If after a week’s delay, the threshold levels were
still not reached, the full blood count was taken again and
treatment was delayed a further week. If after 2 weeks delay the
threshold was not reached, the following dose adjustments were
made:
If either the platelet count or the neutrophil levels were below
the threshold levels, then the lower dose was to be given.
For hepatic or renal impairment, treatment was delayed for 2
weeks until the abnormal result fell within the laboratory normal
range. If after this period the liver or renal function was still
abnormal, the patient was withdrawn from the study. Patients were
withdrawn from the study if neurological toxicity was greater than
WHO grade II.
No maintenance therapy was given as part of this study.
Response evaluation
Patients were clinically assessed after two cycles of therapy. Those
with clinically apparent progressive disease (PD) or with no
response after two cycles were withdrawn from the study. The
remaining patients were assessed after four cycles with CT
scanning. Those in CR or with good partial response (PR)
(475% tumour reduction on CT) received a further two courses
of treatment. Those with a maximum partial response (450%
Table 1 Patient characteristics
Eligible patients (n¼30)
Sex n %
Male 16 53
Female 14 47
Criteria for treatment
Progressive disease 13 43
Critical organ failure 9 30
Symptoms 16 53
Age
Median 55
Range 29–76
Stage
III 14 47
IV 16 53
B symptoms 17 57
WHO PS
01 9 6 3
17 2 3
23 1 0
31 3
IPI
Low 0
Low–intermediate 17 57
Intermediate–high 9 30
High 3 10
Unknown 1 3
Neutrophil count Platelet count % of intended dose of FAD
41.0 10
9l
 1 and 475 10
9l
 1 50%
o1.0 10
9l
 1 and o75 10
9l Off study
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Figure 1 Overall survival and failure-free survival.
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partial response or a total of eight cycles (whichever was the least).
Statistical considerations
The primary end point of the study was regimen-related toxicity
using toxic death rate and toxicity as outcome measures. The
secondary end point was FFS using CR rate, progression-free
survival, disease-free survival and OS as outcome measures. The
survival analyses are presented as Kaplan–Meier survival graphs.
RESULTS
Response rates
The overall response rate in this cohort of patients was 96% with a
CR rate of 39%. If the two patients dying of myocardial infarction
are considered as nonresponders, the overall response rate is 93%.
With a median follow-up of 50 months (range 839–1932 days)
in the 20 patients who are still alive, the actuarial 4-year OS rate is
72% (Figure 1).
In all, 50% of patients have experienced disease progression at
some time during the period of this study. The median time to
treatment failure was 29 months and the actuarial 4-year FFS is
42% (Figure 1).
Toxicity
Haematological toxicity was mild. No significant anaemia was
reported for any of the 181 courses of chemotherapy administered
to patients in this study. In total, 23% of courses of FAD
chemotherapy resulted in significant leucopenia (WHO grade III/
IV). Severe thrombocytopenia was reported in one course only.
Nonhaematological toxicity was rare, with 3% of courses causing
grade III nausea and vomiting, and 7% of patients reporting grade
III alopecia. Mucositis was mild, with grade I or II symptoms
reported in 17 courses of chemotherapy.
Deaths
There were a total of 10 deaths in this cohort of 30 patients. Seven
were due to non-Hodgkin’s lymphoma. Two patients died of
myocardial infarction, one occurring 1 week after the first course
of FAD chemotherapy, and the other occurring 3 weeks after the
sixth course. One patient developed an ischiorectal abscess after
his second course of FAD chemotherapy, which required formal
surgical debridement and a prolonged inpatient stay of several
months. He eventually died of a bronchopneumonia 6 months
after starting treatment (Tables 2–4).
DISCUSSION
This study confirms that a combination of fludarabine, adriamycin
and dexamethasone can be administered with acceptable toxicity
Table 2 Treatment toxicity: haematological (a), non-haematological (b)
Courses for eligible patients
(n¼181)
n %
(a) Haematological toxicity
Hb
0 147 81
12 4 1 3
2 1 0.6
3
4
Unknown 9 5
WBC
09 2 5 1
12 2 1 2
21 6 9
33 6 2 0
46 3
Unknown 9 5
Platelets
0 168 93
1 3 1.5
2
3 1 0.6
4
Unknown 19 10
(b) Nonhaematological toxicity
Oral
0 146 80
16 3
21 1 6
3
4
Unknown 18 10
Nausea and vomiting
0 132 73
11 9 1 0
27 4
35 3
4
Unknown 18 10
Diarrhoea
0 162 90
16 3
2 3 1.5
3
4
Unknown 10 5.5
Neurological
0 158 87
11 3 7
2
3
4
Unknown 10 5.5
Skin
0 164 90
1 1 0.6
2
3
4
Unknown 16 8.8
Alopecia
04 5 2 5
13 2 1 8
24 6 2 5
31 3 7
4
Unknown 45 25
Table 2 (Continued)
Courses for eligible patients
(n¼181)
n %
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lto patients with follicular lymphoma, many of whom are over 60
years of age. The prophylactic use of cotrimoxazole successfully
prevented the development of Pneumocystis carinii infection
without obvious increased haematological toxicity. Only 3% of
cycles resulted in grade 4 neutropenia, and significant thrombo-
cytopenia was even more rare. Nonhaematological toxicity was
also very rare except that two patients suffered fatal myocardial
infarctions to which the adriamycin might have contributed.
The overall response rate in these previously untreated patients
was very high (93%) and accords with the results reported by
Velasquez et al (2003) and Zinzani et al (2000). There is no major
difference in efficacy between the use of adriamycin as in this
study or the use of mitoxantrone as in the regimen developed by
McLaughlin et al (1994, 1996), but only a large randomised trial
would detect small differences.
The response rates to both fludarabine and mitoxantrone
(Zinzani et al, 2000; Velasquez et al, 2003) and to fludarabine,
mitoxantrone and dexamethasone as reported here are markedly
higher than those reported with fludarabine alone. In a phase II
trial of 54 patients reported by Solal-Celigny et al (1996), the
overall response rate to fludarabine was 65%, and in
the Intergroup randomised trial comparing CVP to fludarabine,
the overall response to fludarabine was 69% (Marcus et al, 2002).
Unfortunately, the higher response rate in this study has not
translated into prolonged remissions. The median time to
treatment failure of 29 months is only marginally greater than
the 21 months seen in the Intergroup study with fludarabine alone.
However, if prolonged remissions are to be achieved in a large
proportion of patients with follicular lymphoma, then high initial
responses must first be achieved and the combination of FAD or
FMD are probably the most effective chemotherapy regimens, with
acceptable toxicity, described to date. Additional agents are
required to either consolidate or maintain such responses and
rituximab combined with these regimens merits consideration as
first-line therapy.
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Table 3 Response rates
N¼30 %
Response 30
CR 11 37
PR 16 53
PD 1 3.3
Not evaluable
a (see footnote) 2 6.6
Disease progression 15 50
Status
Alive 20 67
Dead 10 33
aThese two patients died of myocardial infarction, one occurring 1 week after the first
course of chemotherapy and the other 3 weeks after the sixth course. The response
to chemotherapy was therefore not evaluated.
Table 4 Deaths
Cause of death N¼30
NHL 7
Cardiovascular disease 2
Bronchopneumonia 1
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